PTGS2 and breast carcinoma: While intake of COX-2 inhibitors was shown to have chemo-protective effects against breast cancer development and morbidity7, they can cause thrombo-embolic side effects8,9, suggesting the need of identifying better alternative target(s) downstream of COX-2.